Adamis Pharmaceuticals Receives Grant to Develop Treatment for Alcohol Use Disorder
A wholly-owned subsidiary of commercial stage biopharmaceutical company, Adamis Pharmaceuticals (Nasdaq: ADMP), has received a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) for the development of a novel bifunctional small molecule to potentially treat Alcohol Use Disorder.
Adamis says its mission is to become the market leader on interventions for substance use disorders.
Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals, said, “We already have an approved product (ZIMHI) and a clinical stage product candidate (DPI-125) for addressing the opioid crisis, but we also want to expand our development portfolio to include other substance use disorder treatments in areas of high unmet need such as Alcohol Use Disorder.”
The NIAAA grant was awarded to DMK Pharmaceuticals Corporation, a wholly-owned subsidiary of Adamis.
Excessive use of alcohol is estimated to cost the U.S. economy $250 billion a year. Alcohol Use Disorder affected 29.5 million Americans over the age of 12 in 2021.
The NIAAA is one of the 27 Institutes at the National Institutes of Health (NIH), the nation’s medical research agency. It conducts and funds research on the impact of alcohol use.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. Adamis’ commercial products approved by the FDA include ZIMHI® (naloxone) Injection for the treatment of opioid overdose, and SYMJEPI® (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis.